– USA, WA – Receptor Life Sciences today announced the appointment of Mark Theeuwes to its Board of Directors as President and CEO, succeeding Greg Wesner who will remain on the Board of Directors.
“RLS is at an important inflection point with our delivery technologies expected to have INDs in 2021. Mark is an experienced pharmaceutical executive with a proven track record of building clinical and commercial stage organizations. Under Mark’s leadership, RLS is well-positioned for continued success,” said Executive Chairman, Arthur Rubinfeld.
About Mark Theeuwes
Mr. Theeuwes joins RLS following the acquisition of Engage Therapeutics by UCB in June 2020. He served as COO from 2018 until its acquisition, which came following positive data from a large, randomized Phase 2 clinical trial of its lead product candidate in development for a new product category called REST. Before joining Engage, Mr. Theeuwes held positions of increasing responsibility at Egalet, NPS, ViroPharma, OraPharma, Johnson & Johnson, and Alza.
“I am honored and excited to lead RLS and build upon the solid foundation that Greg and the team have established over the last five years,” said Mr. Theeuwes. “Receptor has two promising clinical candidates in its pipeline that may favorably impact millions of patients who today have inadequate therapies. I look forward to progressing the pipeline to bring these therapies to patients in need.”
About Receptor Life Sciences
Receptor Life Sciences is a pharmaceutical company that applies FDA-approved drug-delivery technologies to develop innovative therapies to address central nervous system disorders that have few safe and effective treatments. Receptor Life Sciences uses these technologies to produce inhaled and oral cannabinoid products that hold the potential to provide precision, consistency, reliability, and convenience.
For more information: https://www.receptorlife.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
